Emily Kaiser

Aug 24, 2023 | optometrytimes.com | Emily Kaiser

Tarsus Pharmaceuticals announced that lotilaner ophthtalmic solution (Xdemvy) 0.25% is now ready for prescription as it is available at pharmacies nationwide. The eye drop Xdemvy received FDA approval on July 24, 2023, making it the first and only approved treatment for Demodex blepharitis.

Aug 9, 2023 | optometrytimes.com | Emily Kaiser

Optometry has a representation problem, and Black EyeCare Perspective is challenging the industry to address it with their 13% Promise. As of 2020, 1.8% of practicing optometrists are Black, and in 2021, 3.0% of optometry students are Black. Compare this to the 13% of Black citizens who make up the US population,2 and you can see the disparity of representation in the industry. “There’s a big [gap] in between those 2 numbers.

Jul 28, 2023 | optometrytimes.com | Selina McGee |Dipl ABO |Marlisa Miller |Emily Kaiser

Jul 28, 2023Selina R. McGee, OD, FAAO, Dipl ABOMarlisa Miller, Editorial Intern Emily Kaiser, Assistant Managing EditorDr Selina McGee, OD, FAAO, Dipl ABO, met with Optometry Times to discuss the recent FDA approval of XDEMVY, a treatment for Demodex blepharitis, from Tarsus Pharmaceuticals. XDEMVY, the first and only treatment option for Demodex blepharitis, was approved by the FDA.

Jul 28, 2023 | optometrytimes.com | A. Paul Chous |Emily Kaiser |Marlisa Miller

A. Paul Chous, OD, MA, FAAO, co-chair of the 2023 EyeCon meeting, caught up with Optometry Times®' assistant managing editor, Emily Kaiser, to share the exciting things he's looking forward do for this year's meeting. The third annual EyeCon meeting will be held December 1-2, 2023, at the Marriott Sanibel Harbour Resort & Spa in Sanibel Harbour, Florida. To learn more about the meeting and register, visit PER's website here. TranscriptEditor's note: This transcript has been edited for clarity.

Jul 26, 2023 | optometrytimes.com | Emily Kaiser

Opthea announced that its lead biologic drug candidate OPT-302—which is being evaluated in 2 Phase 3 clinical trials for the treatment of neovascular or wet age-related macular degeneration (wet AMD)—has received its nonproprietary drug name: Sozinibercept (pronounced soe'' zi nib' er sept).